摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

1,1-dimethyl-2-(1-morpholinocarbonylamino)ethylamine | 87484-84-2

中文名称
——
中文别名
——
英文名称
1,1-dimethyl-2-(1-morpholinocarbonylamino)ethylamine
英文别名
1,1-dimethyl-2-(morpholinocarbonylamino)ethylamine;N-(2-Amino-2-methylpropyl)morpholine-4-carboxamide
1,1-dimethyl-2-(1-morpholinocarbonylamino)ethylamine化学式
CAS
87484-84-2
化学式
C9H19N3O2
mdl
——
分子量
201.269
InChiKey
LPMQIFMKQHBZAK-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 沸点:
    408.0±45.0 °C(Predicted)
  • 密度:
    1.106±0.06 g/cm3(Predicted)

计算性质

  • 辛醇/水分配系数(LogP):
    -1.1
  • 重原子数:
    14
  • 可旋转键数:
    2
  • 环数:
    1.0
  • sp3杂化的碳原子比例:
    0.89
  • 拓扑面积:
    67.6
  • 氢给体数:
    2
  • 氢受体数:
    3

SDS

SDS:b8397bed2c2bf8e28e4cc4ee53ace51d
查看

上下游信息

  • 下游产品
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

  • 作为反应物:
    参考文献:
    名称:
    2-hydroxypropylamine heteroaryl ester derivatives
    摘要:
    本发明涉及一般式为##STR1##的化合物,其中Ar代表取代或未取代的杂环基团;W代表1至约10个碳原子的烷基;B代表--NR.sub.2 COR.sub.1,--NR.sub.2 CONR.sub.1 R.sub.3,--NR.sub.2 SO.sub.2 R.sub.1,NR.sub.2 SO.sub.2 NR.sub.1 R.sub.3或--NR.sub.2 COOR.sub.1,其中R.sub.1,R.sub.2和R.sub.3可能相同也可能不同,可以是氢,烷基,烷氧基烷基,环烷基,烯基,炔基,芳基,杂芳基或芳基烷基,但当B为--NR.sub.2 SO.sub.2 R.sub.1或--NR.sub.2 COOR.sub.1时,R.sub.1不是氢,或者R.sub.1和R.sub.3可以与N一起形成5到7成员的杂环基团,以及其药用盐。这些化合物表现出β-肾上腺素受体阻滞活性,并且在青光眼的治疗中也很有用。
    公开号:
    US04798892A1
  • 作为产物:
    描述:
    吗啉1,2-二氨基-2-甲基丙烷N,N'-羰基二咪唑 作用下, 以 氯仿 为溶剂, 以8.74 g (43%)的产率得到1,1-dimethyl-2-(1-morpholinocarbonylamino)ethylamine
    参考文献:
    名称:
    Esters of thiadiazole oxypropanolaine derivatives and pharmaceutical uses
    摘要:
    通用公式为##STR1##的新型化合物,其中R.sub.1是较低的烷基、较低的环烷基、较低的烯基、较低的炔基、较低的烷基羧甲基、芳基羧甲基、芳基或芳基烷基;A是直链键、较低的烷基烯烃或较低的烯烃基;x为1或2,但当x大于1时,##STR2##基的不同发生位置可能相同或不同;Ar为杂环、未取代的芳香族或芳香族取代的较低烷基、较低烯基、较低炔基、较低烷氧基、卤素、乙酰胺基、氨基、硝基、较低烷基氨基、羟基、较低羟基烷基或氰基;W为含有1至约10个碳原子的烷基;B为--NR.sub.2 COR.sub.3、--NR.sub.2 CONR.sub.3 R.sub.4、--NR.sub.2 SO.sub.2 R.sub.3、--NR.sub.2 SO.sub.2 NR.sub.3 R.sub.4或--NR.sub.2 COOR.sub.5,其中R.sub.2、R.sub.3、R.sub.4和R.sub.5可能相同也可能不同,可以是氢、烷基、烷氧基烷基、烷氧基芳基、环烷基、烯基、炔基、芳基、杂环芳基或芳基烷基,但当B为--NR.sub.2 SO.sub.2 R.sub.3或--NR.sub.2 COOR.sub.5时,R.sub.3和R.sub.5不是氢,或者R.sub.3和R.sub.4可以与N一起形成5到7个成员的杂环基团;及其药用盐。
    公开号:
    US04623652A1
点击查看最新优质反应信息

文献信息

  • Development of a Highly Cardioselective Ultra Short-Acting .BETA.-Blocker, ONO-1101.
    作者:Sadahiko IGUCHI、Hiroyuki IWAMURA、Minoru NISHIZAKI、Akio HAYASHI、Kazuhiko SENOKUCHI、Kaoru KOBAYASHI、Katsuhito SAKAKI、Katsutoshi HACHIYA、Yumiko ICHIOKA、Masanori KAWAMURA
    DOI:10.1248/cpb.40.1462
    日期:——
    A novel, highly cardioselective ultra short-acting β-blocker, ONO-1101, has been developed for application in the emergency treatment of tachycardia and better control of heart rate in surgery. This agent is approximately nine times more potent in β-blocking activity in vivo and eight times more cardioselective in vitro than esmolol. This β-blocking drug has a short duration of activity, enabling rapid recovery after cessation of administration if side effects occur. It can be used safely in patients suffering from acute heart disease and represents a major therapeutic advance in the treatment of heart disease.
    一种新型、高度心脏选择性超短效β受体阻滞剂ONO-1101已研发成功,可用于心动过速的紧急治疗和手术中更好地控制心率。该药物在体内的β受体阻断活性比艾司洛尔强约9倍,在体外的心脏选择性比艾司洛尔强8倍。这种β受体阻断药物的作用时间短,如果出现副作用,停药后即可迅速恢复。它可安全用于急性心脏病患者,是心脏病治疗领域的一大进步。
  • Ultra-short-acting .beta.-adrenergic receptor blocking agents. 3. Ethylenediamine derivatives of (aryloxy)propanolamines having esters on the aryl function
    作者:Paul W. Erhardt、Chi M. Woo、William L. Matier、Richard J. Gorczynski、William G. Anderson
    DOI:10.1021/jm00362a004
    日期:1983.8
    Various ethylenediamine derivatives have been incorporated into the nitrogen substituent of certain short-acting (aryloxy)propanolamine systems that contain esters on their aryl functions. Although several of these compounds showed durations of action comparable to their prototypes, most of the nitrogen substituents significantly prolonged the duration of beta-adrenergic blockade. Similarly, while one of the compounds showed appreciable cardioselectivity in vitro, generally, little enhancement of cardioselectivity was obtained. A brief discussion of structure-activity relationships observed for the ethylenediamine derivatives is presented.
  • [(Arylcarbonyl)oxy]propanolamines. 1. Novel .beta.-blockers with ultrashort duration of action
    作者:Sheung Tsam Kam、William L. Matier、Khuong X. Mai、Cynthia Barcelon-Yang、Robert J. Borgman、John P. O'Donnell、Herman F. Stampfli、Check Y. Sum、William G. Anderson
    DOI:10.1021/jm00374a013
    日期:1984.8
    Novel [(arylcarbonyl)oxy]propanolamines were synthesized and investigated as potential ultrashort-acting beta-adrenergic receptor blockers. Many of these analogues exhibited good potency and short duration. The N-ureidoalkyl analogue 85 (ACC-9089) has a potency equal to propranolol and a duration of action of about 21 min in the dog. It has been selected as a candidate for further clinical study. Structure-activity relationships and structure-duration relationships for these new beta-blockers are also discussed.
  • KAM, S. T.;MATIER, W. L.
    作者:KAM, S. T.、MATIER, W. L.
    DOI:——
    日期:——
  • ESTERS OF ARYLOXYPROPANOLAMINE DERIVATIVES AND USE AS BETA-ADRENERGIC BLOCKING AGENTS
    申请人:AMERICAN HOSPITAL SUPPLY CORPORATION
    公开号:EP0093155B1
    公开(公告)日:1986-08-27
查看更多